Olink Holding Ab (Publ) Stock Price, News & Analysis

The global Hemato Oncology Testing market is poised for significant growth, expected to reach USD 5.6 billion by 2027 from USD 2.9 billion in 2022 at a CAGR of 14.2%. This growth is driven by the rising incidence of hematologic cancers, an increase in clinical collaborations, and a growing emphasis on personalized medicine.

The services segment dominated the market in 2021, attributed to the need for continuous patient monitoring. The lymphoma segment displayed the highest CAGR among cancer types, supported by the increasing prevalence of lymphoma and an aging population. Technologically, PCR showed the highest growth within the testing market due to its ease of use.

Geographically, the Asia-Pacific region is expected to see the most robust growth, fueled by a rising geriatric population and enhanced healthcare demand.

On April 17, 2023, Olink Holding AB held its Annual General Meeting (AGM), where key resolutions were passed. The AGM adopted the balance sheet and income statement, with no dividend declared for the financial year 2022, opting instead to capitalize the funds. Board Members and the CEO received discharge from liability for the prior year.

A total remuneration of USD 640,000 for the Board of Directors was approved, alongside the election of new Board Member Dr. Gregory J. Moore. Ernst & Young AB was appointed as the auditor. Additionally, two Long Term Incentive programs were introduced, potentially diluting shares by 0.06% and 0.73% respectively. The Board was authorized to issue new shares, allowing for a potential dilution of up to 20% of total shares.

Olink Holding AB (Nasdaq: OLK) announced that it will release its financial results for Q1 2023 on May 11, 2023, before the market opens. Management will host a conference call at 8:00 AM ET to discuss these results. Investors wishing to participate are advised to register in advance. The company focuses on advancing proteomics in collaboration with the scientific community, impacting various disease areas to enhance patient outcomes. Established in 2016, Olink operates globally, with a robust presence in Europe, North America, and Asia.

Olink Holding AB (Nasdaq: OLK) announced the adoption of its technology by the D-CYPHR facility in Cape Town, South Africa, marking the first service provider utilizing Olink^® Target and Olink^® Flex platforms for targeted protein biomarker discovery in Africa. D-CYPHR, co-founded by the Centre for Proteomic and Genomic Research and the Institute of Infectious Disease and Molecular Medicine, aims to support complex clinical research. The facility plans to use Olink technology for projects focusing on COVID-19 and tuberculosis, enhancing research capabilities and potential health outcomes in African populations.

Olink Holding AB (Nasdaq: OLK) has released its Annual Report for 2022, now accessible on its website. The report outlines the company's ongoing commitment to advancing proteomics in collaboration with the scientific community, aiming to facilitate new discoveries across various disease areas. Founded in 2016 and headquartered in Uppsala, Sweden, Olink operates internationally, providing a platform of products and services utilized by major biopharmaceutical companies, clinical, and academic institutions. This initiative is designed to enhance the understanding of human biology and drive impactful healthcare advancements.

Olink Holding AB (Nasdaq: OLK) has appointed Bruno Rossi as Chief Commercial Officer (CCO), effective immediately. Rossi brings over 25 years of experience in the life sciences sector, having held senior positions at Leica Microsystems and Millipore. He will oversee the global commercial team at Olink, focusing on sales, marketing, and operations. Carl Raimond, President of Olink, expressed confidence in Rossi's ability to drive growth within the rapidly evolving proteomics industry. Olink aims to utilize its cutting-edge technology to enhance market leadership and achieve significant commercial objectives moving forward.